3 Biotech Stocks to Watch for Respectable Growth Beyond AI
Three biotech companies, Cytokinetics, Madrigal Pharmaceuticals, and ADMA Biologics, reported strong Q4 2025 results and have catalysts that should drive growth through 2026 and beyond. These companies have approved products generating meaningful revenue and are building commercial businesses around recently approved drugs.
Three biotech stocks are showing respectable growth. Cytokinetics' MYQORZO received FDA approval in December 2025, with Q4 2025 revenue at $17.75 million, beating consensus by 121%. Madrigal Pharmaceuticals' Rezdiffra posted Q4 2025 net sales of $321.10 million, up 211% year over year. ADMA Biologics reported Q4 2025 revenue of $139.16 million, up 18% year over year, and is the only profitable name on the list. Cytokinetics has a calendar of catalysts, including ACACIA-HCM topline results in Q2 2026. Madrigal has extended U.S. patent protection to 2045 and has a pipeline spanning more than 10 programs. ADMA Biologics' ASCENIV generated $362.53 million in 2025, up 51%, with guidance calling for 2026 revenue above $635 million.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.